CorMedix is a commercial-stage pharmaceutical company focused on the treatment of infectious, inflammatory, and other serious diseases. The company markets Neutrolin, a catheter lock solution for the prevention of catheter related bloodstream infections. Neutrolin is approved as a CE Marked medical device in Europe where it was shown to reduce catheter-related bloodstream infections by 96% and thrombosis by 96.7%. Founded in 2006, it is based in Bridgewater, New Jersey.